Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Prognostic Factors for Survival after Allogeneic Transplantation in Acute Lymphoblastic Leukemia

Christine Greil, Monika Engelhardt, MD, Gabriele Ihorst, Hartmut Bertz, MD, Reinhard Marks, MD, Robert Zeiser, MD, Justus Duyster, MD, Jürgen Finke, MD, Ralph Wäsch, MD

Blood (2019) 134 (Supplement_1): 4597.

https://doi.org/10.1182/blood-2019-130146

Published: 2019

Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 3120.

https://doi.org/10.1182/blood-2019-124349

Published: 2019

Journal Articles

Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells

Mara N Zeissig, BS, Duncan R Hewett, PhD, Krzysztof M Mrozik, PhD, Vasilios Panagopoulos, PhD, Monika Engelhardt, MD, Luen Bik To, MBBS, FRACP, FRCPA, PhD, Peter J Croucher, PhD, Andrew CW Zannettino, PhD, Kate Vandyke, PhD

Blood (2019) 134 (Supplement_1): 3099.

https://doi.org/10.1182/blood-2019-121974

Published: 2019

Journal Articles

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Blood (2019) 134 (Supplement_1): 1840.

https://doi.org/10.1182/blood-2019-125235

Published: 2019

Journal Articles

A Novel 10-Fluorochrome Multiparameter Flow Cytometry (MFC) Panel for Precise Plasma Cell (PC) and MRD Assessment in Clinical Routine of Multiple Myeloma (MM) Patients and throughout the Disease Course

Veronika Riebl, Sandra M. Woerner, Dagmar Wider, Marie Follo, Stefan J. Mueller, Cornelius Miething, Mihaela Zlei, Justus Duyster, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2019) 134 (Supplement_1): 1789.

https://doi.org/10.1182/blood-2019-124680

Published: 2019

Journal Articles

The Revised Myeloma Comorbidity Index (R-MCI) As a Promising Approach for Predicting Overall (OS)- and Progression-Free (PFS) Survival and Optimizing Therapy Strategies in Multiple Myeloma (MM) Patients (pts) - Comparative Analysis of 5 Comorbidity Indices (CI), Including Retro- and Prospective Applicability

Katja Schoeller, Gabriele Ihorst, Sophia Scheubeck, Max Holler, Sandra M. Woerner, Heike Reinhardt, Stefan P. Müller, Justus Duyster, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2019) 134 (Supplement_1): 3474.

https://doi.org/10.1182/blood-2019-127030

Published: 2019

Journal Articles

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Katja Weisel, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo

Blood (2019) 134 (Supplement_1): 3480.

https://doi.org/10.1182/blood-2019-122232

Published: 2019

Journal Articles

MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study

Marc S Raab, MD PhD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor Blau, MD PhD, Hermann Einsele, MD, Monika Engelhardt, MD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Rollig, MD MSC, Katja Weisel, MD, Tiantom Jarutat, MD, Dominika Weinelt, MD, Mark Winderlich, PhD, Christian Peschel, MD

Blood (2018) 132 (Supplement 1): 153.

https://doi.org/10.1182/blood-2018-153

Published: 2018

Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

Meletios A Dimopoulos, MD, Katja Weisel, MD, Philippe Moreau, Larry Anderson, MD PhD, Darrell J White, MD, Jesus F San-Miguel, MD PhD, Pieter Sonneveld, MD PhD, Monika Engelhardt, MD, Matthew W Jenner, Alessandro Corso, MD, Jan Dürig, Michel Pavic, MD, Morten Salomo, Xin Yu, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Mohamed Zaki, MD PhD, Paul Richardson

Blood (2018) 132 (Supplement 1): 3278.

https://doi.org/10.1182/blood-2018-99-111869

Published: 2018

Journal Articles

Minimal Residual Disease (MRD) Analysis Using Multiparametric Flow Cytometry (MFC) and Identification of Differences in Subpopulations Using Next Generation Sequencing (NGS) in the Bone Marrow (BM) of Multiple Myeloma (MM) Patients (pts)

Sandra M. Dold, MSc, BSc, Veronika Riebl, Dagmar Wider, Marie Follo, PhD, Stefan J. Mueller, Ingrid Bartsch, Milena Pantic, PhD, Cornelius Miething, MD, Chrissoula Kiote-Schmidt, K. Martin Kortüm, MD, Mihaela Zlei, Abdel Kareem Azab, PhD, Mascha Binder, MD, Justyna Rawluk, Justus Duyster, Prof., Robert Zeiser, MD, Ralph Wäsch, MD, Monika Engelhardt, MD

Blood (2018) 132 (Supplement 1): 3222.

https://doi.org/10.1182/blood-2018-99-112489

Published: 2018

Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Katja Weisel, MD, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Ashlee Espensen, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo, MD

Blood (2018) 132 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2018-99-112080

Published: 2018

Journal Articles

Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT)

Blood (2018) 132 (Supplement 1): 1979.

https://doi.org/10.1182/blood-2018-99-116067

Published: 2018

Journal Articles

PIM1-Mediated CXCR4 Phosphorylation: A Potentially Class-Distinct Therapeutic Target of Next Generation Proteasome Inhibitors in Multiple Myeloma

Johannes M. Waldschmidt, MD, Dagmar Wider, Stefan J. Müller, Dipl.-Pharm., Anna Simon, Sarah Decker, PhD, Marie Follo, PhD, Justus Duyster, MD PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 2774.

https://doi.org/10.1182/blood.V128.22.2774.2774

Published: 2016

Journal Articles

Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 Multiple Myeloma Patients

Maximilian Schinke, Inga Promny, MD, Gabriele Ihorst, PhD, Johannes M. Waldschmidt, MD, Roland H. Mertelsmann, MD PhD, Justus Duyster, MD, Ralph M. Waesch, MD, Martin Schumacher, PhD, Monika Engelhardt, MD

Blood (2016) 128 (22): 5953.

https://doi.org/10.1182/blood.V128.22.5953.5953

Published: 2016

Journal Articles

Functional Geriatric Assessment (F-GA) in Multiple Myeloma Patients: Results from a Prospective Multicenter Study Group (DSMM) Trial and Changes from Baseline to Follow-up Assessment

Sophia Scheubeck, Sandra Maria Dold, M. Sc., Gabriele Ihorst, PhD, Alexander Zober, MD, Stefan J. Müller, Dipl.-Pharm., Christian Langer, MD, Wolfram Pönisch, Lars-Olof Mügge, MD, Stefan Knop, MD, Justus Duyster, MD, Martin Schumacher, PhD, Ralph M. Waesch, MD, Monika Engelhardt, MD

Blood (2016) 128 (22): 5627.

https://doi.org/10.1182/blood.V128.22.5627.5627

Published: 2016

Journal Articles

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Marc S. Raab, MD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor Blau, Hermann Einsele, MD, Monika Engelhardt, MD PhD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Röllig, MD, Katja Weisel, MD, Tiantom Jarutat, MD, Dominika Weinelt, MD, Jan Endell, PhD, Rainer Boxhammer, PhD, Christian Peschel, MD

Blood (2016) 128 (22): 1152.

https://doi.org/10.1182/blood.V128.22.1152.1152

Published: 2016

Journal Articles

The APC/C Coactivator Cdh1 Controls Self-Renewal and Differentiation of Human and Murine HSPCs

Daniel Ewerth, Stefanie Kreutmair, Andrea Schmidts, Marie Follo, PhD, Dagmar Wider, Julia B. Schueler, DVM, PhD, Julia Felthaus, Justus Duyster, MD, Anna Lena Illert, MD, Monika Engelhardt, MD PhD, Wäsch Ralph, MD

Blood (2016) 128 (22): 2650.

https://doi.org/10.1182/blood.V128.22.2650.2650

Published: 2016

Journal Articles

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

Stefan J. Müller, Dipl.-Pharm., Johannes M. Waldschmidt, MD, Johanna Senger, PhD, Dagmar Wider, Andreas R. Thomsen, MD, Gabriele Ihorst, PhD, Justus Duyster, MD, Martin J. Hug, PhD, Manfred Jung, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 2109.

https://doi.org/10.1182/blood.V128.22.2109.2109

Published: 2016

Journal Articles

Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma

Blood (2016) 128 (22): 516.

https://doi.org/10.1182/blood.V128.22.516.516

Published: 2016

Journal Articles

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

Giulia Graziani, Gabriele Ihorst, PhD, Johannes M. Waldschmidt, MD, Georg W. Herget, MD PhD, Karl Henne, MD, Annette M. May, Justus Duyster, MD, Werner Vach, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 5979.

https://doi.org/10.1182/blood.V128.22.5979.5979

Published: 2016

NARROW

Prognostic Factors for Survival after Allogeneic Transplantation in Acute Lymphoblastic Leukemia

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

A Novel 10-Fluorochrome Multiparameter Flow Cytometry (MFC) Panel for Precise Plasma Cell (PC) and MRD Assessment in Clinical Routine of Multiple Myeloma (MM) Patients and throughout the Disease Course

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study

Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

Minimal Residual Disease (MRD) Analysis Using Multiparametric Flow Cytometry (MFC) and Identification of Differences in Subpopulations Using Next Generation Sequencing (NGS) in the Bone Marrow (BM) of Multiple Myeloma (MM) Patients (pts)

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT)

PIM1-Mediated CXCR4 Phosphorylation: A Potentially Class-Distinct Therapeutic Target of Next Generation Proteasome Inhibitors in Multiple Myeloma

Evaluation of the Risk of Relapse and Survival Using a Conditional Survival Approach in 815 Multiple Myeloma Patients

Functional Geriatric Assessment (F-GA) in Multiple Myeloma Patients: Results from a Prospective Multicenter Study Group (DSMM) Trial and Changes from Baseline to Follow-up Assessment

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

The APC/C Coactivator Cdh1 Controls Self-Renewal and Differentiation of Human and Murine HSPCs

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma

Time from First Symptom Onset to the Final Diagnosis of Multiple Myeloma - Possible Risks and Future Solutions: Large Retrospective and Confirmatory Prospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only